Lessons From Mercosur Multi-Country Pricing Negotiations
Latin American joint price negotiations have proved successful and other countries are taking note.
You may also be interested in...
Latin American countries are continuing to pursue a strategy of jointly negotiating medicine prices to get a better deal on expensive medicines. However, manufacturers have expressed doubt that this is the best way forward.
Pharmaceutical companies wanting to sell high-cost drugs in Latin America may find themselves talking with multiple countries at once to find a single acceptable price. Mercosur member and associate countries are wielding their collective might to secure lower prices through a new negotiation mechanism supported by the Pan American Health Organization / World Health Organization. Mercosur health ministers have already announced an offer from Gilead to supply its hepatitis C drug Sovaldi (sofosbuvir) and next up for discussion are likely to be costly cancer medicines.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.